tcsc2945 Mifamurtide

Mifamurtide(CGP19835; MTP-PE) is a drug against osteosarcoma.

Target: Others

Mifamurtide is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma [1]. Mifamurtide has orphan drug status for the treatment of osteosarcoma in the US and EU [2].